201 related articles for article (PubMed ID: 15331725)
21. The danger molecule HMGB1 cooperates with the NLRP3 inflammasome to sustain expression of the EBV lytic switch protein in Burkitt lymphoma cells.
Reinhart NM; Akinyemi IA; Frey TR; Xu H; Agudelo C; Brathwaite J; Burton EM; Burgula S; McIntosh MT; Bhaduri-McIntosh S
Virology; 2022 Jan; 566():136-142. PubMed ID: 34922257
[TBL] [Abstract][Full Text] [Related]
22. B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.
Chen Y; Fachko DN; Ivanov NS; Skalsky RL
mSphere; 2021 Apr; 6(2):. PubMed ID: 33853871
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus latency programs dynamically sensitize B cells to ferroptosis.
Burton EM; Voyer J; Gewurz BE
Proc Natl Acad Sci U S A; 2022 Mar; 119(11):e2118300119. PubMed ID: 35275790
[TBL] [Abstract][Full Text] [Related]
24. Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.
Ye J; Gradoville L; Miller G
J Virol; 2010 Dec; 84(23):12405-18. PubMed ID: 20861250
[TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.
Menezes J; Leibold W; Klein G; Clements G
Biomedicine; 1975 Jul; 22(4):276-84. PubMed ID: 179629
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
28. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
Miyauchi K; Urano E; Yoshiyama H; Komano J
Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
[TBL] [Abstract][Full Text] [Related]
29. Somatic mutations and activation-induced cytidine deaminase (AID) expression in established rheumatoid factor-producing lymphoblastoid cell line.
Gil Y; Levy-Nabot S; Steinitz M; Laskov R
Mol Immunol; 2007 Jan; 44(4):494-505. PubMed ID: 16574227
[TBL] [Abstract][Full Text] [Related]
30. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
[TBL] [Abstract][Full Text] [Related]
31. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
33. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
[TBL] [Abstract][Full Text] [Related]
34. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin.
Goldfeld AE; Liu P; Liu S; Flemington EK; Strominger JL; Speck SH
Virology; 1995 May; 209(1):225-9. PubMed ID: 7538254
[TBL] [Abstract][Full Text] [Related]
36. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
Komano J; Sugiura M; Takada K
J Virol; 1998 Nov; 72(11):9150-6. PubMed ID: 9765461
[TBL] [Abstract][Full Text] [Related]
38. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
39. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
40. Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.
Takeda S; Kanbayashi D; Kurata T; Yoshiyama H; Komano J
Cancer Sci; 2014 Feb; 105(2):211-8. PubMed ID: 24238277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]